Emerging evidence suggests that AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptor alpha (PPARα) and LC3 are critical regulators of hepatic lipid metabolism and could be therapeutic targets in NAFLD [10]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.